Protagonist Therapeutics

Yahoo Finance • 11 hours ago

Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more

Here's a list of key deals reported across sectors this week: * Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall... Full story

Yahoo Finance • yesterday

Protagonist Stock Surges on Johnson & Johnson Report

Protagonist Therapeutics shares soared more than 30% Friday after The Wall Street Journal reported that the biopharma company was in talks with Johnson & Johnson about a possible acquistion. See more ... Continue Reading Visualizza comme... Full story

Yahoo Finance • yesterday

Trump's China tariff threat sinks stocks, Applied Digital surges

Yahoo Finance Anchor Josh Lipton reports on three stories Wall Street is watching in the latest Market Minute: US stocks tumble as US-China trade tensions intensify, Protagonist Therapeutic (PTGX) shares surge on WSJ reports of acquisition... Full story

Yahoo Finance • yesterday

Sector Update: Health Care Stocks Decline Friday Afternoon

Health care stocks were lower Friday afternoon, with the NYSE Health Care Index and the Health Care PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 2 days ago

Top Midday Gainers

Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more

Check out the companies making the biggest moves midday: Rare earth stocks — The group rose broadly after President Donald Trump said China was holding the world "captive" over the minerals, threatening countermeasures. MP Materials traded... Full story

Yahoo Finance • 2 days ago

Protagonist Therapeutics stock surges after J&J acquisition talks report

Investing.com -- Protagonist Therapeutics (NASDAQ:PTGX) stock spiked 10% before being halted for volatility after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ) is in talks to acquire the biotech company. The potential... Full story

Yahoo Finance • 2 days ago

J&J reportedly in talks to buy Protagonist

Protagonist Therapeutics (NASDAQ:PTGX [https://seekingalpha.com/symbol/PTGX]), a biotech focused on peptide-based therapeutics, traded ~30% higher on Friday after The Wall Street Journal reported that Johnson & Johnson (NYSE:JNJ [https://s... Full story

Yahoo Finance • 3 days ago

Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says

Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics ( PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

We Did The Math IJR Can Go To $133

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 2 months ago

Protagonist therapeutics CEO Patel sells $570k in stock

Protagonist Therapeutics (NASDAQ:PTGX) President and CEO Dinesh V. Patel, Ph.D., sold 10,415 shares of common stock on July 25, 2025, at prices ranging from $54.75 to $54.82, for a total value of $570,533. The sale comes as the $3.48 billi... Full story

Yahoo Finance • 2 months ago

XSMO's Underlying Holdings Could Mean 15% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 months ago

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head... Full story

Yahoo Finance • 3 months ago

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story

Yahoo Finance • 4 months ago

Protagonist Therapeutics' SWOT analysis: promising pipeline drives stock outlook

Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biopharmaceutical company focused on developing novel therapies, has been making significant strides in its drug development pipeline. The company’s recent advancements in its lead candidates... Full story

Yahoo Finance • 4 months ago

For Patients With Rare Blood Cancer, New Drug Offers Relief

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening their blood and increasing the risk for cl... Full story

Yahoo Finance • 5 months ago

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. Small-cap stocks experienced a significant drop... Full story

Yahoo Finance • 8 months ago

Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now.In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against the other cheap biotech stocks. Biotech Stocks F... Full story

Yahoo Finance • last year

Turnstone Biologics Appoints William Waddill to its Board of Directors

Turnstone Biologics Corp. SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure... Full story